Axsome Therapeutics, Inc. (AXSM)

69,71 +0,90 (+1,31%) Börsenschluss: 04:00PM EDT

Axsome Therapeutics, Inc.

One World Trade Center
22nd Floor
New York, NY 10007
United States
212 332 3241
https://www.axsome.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 545

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Herriot Tabuteau M.D.	Founder, Chairman, CEO & President	1,32M	N/A	1968
Mr. Nick Pizzie CPA, M.B.A.	Chief Financial Officer	732,94k	N/A	1975
Mr. Mark L. Jacobson	COO & Secretary	784,66k	N/A	1983
Mr. Hunter Murdock Esq.	General Counsel & Secretary	735,39k	N/A	1980
Dr. Amanda Jones Pharm.D.	Senior Vice President of Clinical Development	N/A	N/A	1983
Ms. Lori Englebert M.B.A.	Executive Vice President of Commercial & Business Development	N/A	N/A	1978
Joseph Debrah-Afful CPA, M.B.A.	Director of Finance	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Corporate Governance

Axsome Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 8. Die grundlegenden Scores sind Audit: 8, Vorstand: 8, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.